Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This clinical case report describes a patient with ulcerative colitis whose symptoms improved using the Janus kinase inhibitor, tofacitinib, allowing disease remission and hair regrowth.

Certain immune cells in atopic dermatitis skin could be targeted for treatment.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

This case report describes a patient with alopecia universalis who had an excellent and persistent response to oral tofacitinib treatment after one year.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

This case report describes a carpenter who presented with contact dermatitis and trichopathy with whitish nodules in the axillary hair.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study found that nearly half of the tinea capitis patients at a Surabaya hospital had cat contact, with the most common symptoms being crust and hair loss.

This study observed that patients with acute alopecia areata treated with Janus kinase inhibitors achieved a higher rate of complete hair regrowth by week 24 compared to those with non-acute disease, highlighting the benefits of early intervention.

In this study, tofacitinib showed significant efficacy in treating alopecia totalis and universalis over a 6-month period, with notable hair regrowth outcomes, while younger age of onset and shorter treatment duration were linked to less effectiveness.

NFATc1 controls hair stem cell activity, affecting hair growth and could be a target for hair loss treatments.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

This overview highlights the Dermatologic Surgery journal's comprehensive coverage of skin surgery procedures and techniques, but it reports no new research findings.

This study found that modified microcrystalline cellulose with citric and ascorbic acid demonstrated enhanced hemostatic properties and biocompatibility in vitro and in animal hemorrhage models.

This study found that Hataedock may alleviate atopic dermatitis symptoms in mice by maintaining skin homeostasis and improving skin barrier formation through the endocannabinoid system.

This study observed that a tacrolimus solution (0.1%) applied to the scalp was effective and well-tolerated for treating inflammatory scalp conditions, with 72.7% of patients showing an excellent response after 2 months of treatment, which persisted after 6 months.

This study found that patients with central centrifugal cicatricial alopecia were less likely to report treatment improvement and more commonly associated with certain hairstyling practices compared to those with other scarring alopecias.

This review discusses central centrifugal cicatricial alopecia in adult women of African descent and reports no clinical results; the authors highlight traditional treatments and their impact on quality of life.

CTE can distort results in hair growth trials, so exclude it carefully.

This paper discusses a case of acrodermatitis continua that was resistant to treatment with etanercept, highlighting the therapeutic challenges faced, but reports no new research results.

This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.

This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.

This study found that adjuvant docetaxel treatment for breast cancer at cumulative doses of 400 mg/m² or higher is associated with a 10% prevalence of persistent alopecia leading to wig use, but this was completely prevented with scalp cooling.